

Note: the clinical conditions included in this table are placed here as a way of separating the conditions into two tables and does not imply a formal definition of "systemic rheumatologic health conditions"

BMD = bone mineral density; CTD-ILD = connective tissue disease-interstitial lung disease; HCU= Health care utilization; LVV=Large vessel vasculitis; SLE = Systemic Lupus Erythematosis;

1. Osteoporosis: core set depends on focus of trial, ² core domains for randomized trials where prevention of rapid bone loss is the primary aim, ³ core domains for randomized clinical trials of therapies for treating high risk patients for osteoporotic fractures
4. BMD measured at 2 sites: hip and spine
5. If impact of symptoms is specified, these would fall under Impact
6. Mandatory in specific circumstances: these domains should be measured in trials targeting either or all these symptoms.
7. Organ systems named to be mandatory in specific circumstances: mucocutaneous, eye, central nervous system, vascular, musculoskeletal, gastrointestinal.
8. Reporting of adverse events (including death) is mandatory in trials

References

Wolfe 1999

Wolfe F, Lasserre M, van der Heijde D, et al: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. *J Rheumatol* 1999; 26:484-489

Boers 2014

Boers M, Kirwan, JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. *J Clin Epidemiol* 2014; 67: 745-753

Boers 2018

Boers M, Beaton D, Shea B, Maxwell LJ, Bartlett S, Bingham III C, et al. OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. *J Rheumatol* 2019. 46(8):1021-1027

Smolen 1999

Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized Clinical Trials and Longitudinal Observational Studies in Systemic Lupus Erythematosus: Consensus on a Preliminary Core Set of Outcome Domains. *J Rheumatol* 1999;26:504-7

Merkel 2011

Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-Associated Vasculitis. *J Rheumatol* 2011;38:1480-1486

Sreih 2017

Sreih AG, Alibaz-Oner F, Kermani TA, Aydin SZ, Cronholm PF, Davis T, et al. Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. *The Journal of Rheumatology* Dec 2017, 44 (12) 1933-1937; DOI: 10.3899/jrheum.161467

Mease 2009

Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, et al. Fibromyalgia Syndrome Module at OMERACT 9: Domain Construct. *J Rheumatol* 2009;36:2318-29

Sambrook 1997

Sambrook PN, Cummings SR, Eisman JA, Genant HK, Eastell R, Reginster JY, et al. Guidelines of Osteoporosis Trials. *J Rheumatol* 1997; 24:1234-1236

Khanna 2015

Khanna D, Mitto S, Aggarwal R, Proudman SM, Dalbeth N, Matteson E, et al. Connective Tissue Disease-associated Interstitial Lung Diseases—Report from OMERACT CTD-ILD Working Group. *J Rheumatol* 2015; 42: 2168-2171

Regardt 2019

Regardt M, Mecoli C, Park JK, de Groot I, Sarver C, Needham M, et al. OMERACT 2018 Modified Patient-Reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies. *J Rheumatol* 2019;46:1351-4; doi:10.3899/jrheum.181065

Hatemi 2022

Hatemi G, Meara A, Özgüler Y, Direskeneli H, Mahr A, Shea B, et al. Outcome Measures in Rheumatology Behçet's Syndrome Working Group. Core Set of Domains for Outcome Measures in Behçet's Syndrome. *Arthritis Care Res (Hoboken)*. 2022 Apr;74(4):691-699. doi: 10.1002/acr.24511.